Lincoln Pharmaceuticals Limited has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from January 01, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter ended December 31, 2025. The Board of Directors will convene a meeting to approve these financial results, with the exact date to be communicated in due course. During the trading window closure period, all Directors, Senior Management Personnel, Promoters, Promoter Group, their immediate relatives, and other connected persons are advised against trading in the company's securities. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's adopted Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information.